Topotecan and the treatment of recurrent ovarian cancer: is there a role for granulocyte colony-stimulating factor?

L. Saltz, John Edward Janik

Research output: Contribution to journalReview articlepeer-review

4 Scopus citations

Abstract

Topotecan (Hycamtin; SmithKline Beecham Pharmaceuticals, Philadelphia, PA) a new chemotherapeutic agent for the treatment of patients with advanced carcinoma of the ovary after failure of initial or subsequent therapy, is a specific, potent inhibitor of the enzyme topoisomerase I. Myelosuppression is the dose-limiting toxicity of topotecan, and can interfere with the administration of the recommended dose/schedule of the drug by delaying the next cycle of chemotherapy or by requiring a reduction in the dose. The results from clinical studies suggest that routine granulocyte colony-stimulating factor therapy is not needed when topotecan is administered at the recommended dose of 1.5 mg/m2/d for 5 days. However, patients should be carefully monitored, as some may benefit from hematopoietic growth factor support on subsequent cycles.

Original languageEnglish (US)
JournalSeminars in Oncology
Volume24
Issue number1 Suppl 5
StatePublished - Jan 1 1997

ASJC Scopus subject areas

  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Topotecan and the treatment of recurrent ovarian cancer: is there a role for granulocyte colony-stimulating factor?'. Together they form a unique fingerprint.

Cite this